Pfizer (PFE) Intrinsic Value Calculator

Updated: Nov 17, 2026

Pfizer (PFE) trades at $28.45 against a base-case intrinsic value of $17.25 — roughly a 65% premium to fair value. The model starts from $2.95 in expected earnings per share, grows it at -3.4% annually (analyst consensus) decaying to a 4% terminal rate by Year 5, applies a 9.3x exit multiple, and discounts the result back at 10% per year. At today's price, the market is pricing in either faster earnings growth or a higher exit multiple than PFE's own history supports. Use the sliders below to see what growth assumptions would be needed to justify the current price.

Overvalued by 39.4%
Current Price
$28.45
Intrinsic Value
$17.25
Implied Upside: -39.4%

Discounted Cash Flow with Growth Decay Model

Customize Your Valuation

Adjust the assumptions below to model different scenarios. The intrinsic value updates in real-time.

Conservative
Base Case
Aggressive
Time Horizon 5 years
3 years 10 years
Initial Growth Rate -3.4%
0% (No Growth) 50% (High Growth)
Terminal Growth Rate 4.0%
0% (Decline) 6% (GDP+)
Discount Rate (Required Return) 10.0%
5% (Low Risk) 15% (High Risk)
Exit PE Multiple 9.3x
8x (Value) 40x (Growth)
Calculated Intrinsic Value
$17.25
--
Tradestie Long-Horizon Cycle Intelligence (2007–2025 • Split-Invariant)

Tradestie Long-Horizon Financial Resilience & Peer Growth Benchmark (17-Year Cycle Analysis)

Outside-View Peer Growth Benchmark Pharmaceutical Preparations • 2498+ US Equities Benchmarked

Across 19 years of multi-cycle financial history in Pharmaceutical Preparations, only 33.2% of peer companies at >$10B revenue scale (196 historical 5-year windows; industry median CAGR: 2.9%/yr) sustained ≥5%/yr 5-year compound revenue growth (broad >$10B equity base rate: 39.7%).

≥5%/yr (5Y)
33.2%
All >$10B: 39.7%
≥10%/yr (5Y)
13.8%
All >$10B: 15.2%
≥15%/yr (5Y)
7.1%
All >$10B: 6.3%
≥20%/yr (5Y)
2.0%
All >$10B: 3.0%
≥25%/yr (5Y)
0.0%
All >$10B: 1.8%
≥30%/yr (5Y)
0.0%
All >$10B: 1.2%
17-Yr Revenue Scale
$48.42B → $62.58B
18Y CAGR: +1.4%/yr • 5Y: +8.5%
2008–2009 Cycle Trough Floor
Post-2009 Series
Tracked from FY2007
2022 Rate-Shock Floor
N/A
No 2022–2023 operating row
Latest vs Cycle Median Margin
N/A vs --% med
Cyclical Margin Profile — Stress-Test Exit Multiples
Multi-Cycle Revenue & Operating Margin Trajectory (2007–2025) Expansion 2008–09 / 2022 Macro Stress
'07
'08
'09
'10
'11
'12
'13
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Inspect All 17 Fiscal Years of Annual Revenue & Operating Margin History Toggle Annual Ledger ↓
Fiscal Year Annual Revenue YoY Growth Operating Income Operating Margin Macro Cycle Regime
FY2025 (2025-12) $62.58B -1.6% N/A — Standard
FY2024 (2024-12) $63.63B +25.0% N/A — Standard
FY2023 (2023-12) $50.91B -44.5% N/A — Standard
FY2022 (2022-12) $91.79B +24.7% N/A — 2022 Rate Shock
FY2021 (2021-12) $73.64B +76.8% N/A — Standard
FY2020 (2020-12) $41.65B +1.8% N/A — Standard
FY2019 (2019-12) $40.91B +0.2% N/A — Standard
FY2018 (2018-12) $40.83B -22.3% N/A — Standard
FY2017 (2017-12) $52.55B -0.5% N/A — Standard
FY2016 (2016-12) $52.82B — N/A — Standard
FY2013 (2013-12) $51.58B -5.6% N/A — Standard
FY2012 (2012-12) $54.66B -10.4% N/A — Standard
FY2011 (2011-12) $61.03B -6.3% N/A — Standard
FY2010 (2010-12) $65.17B +32.3% N/A — Standard
FY2009 (2009-12) $49.27B +2.0% N/A — 2008–09 Cycle Stress
FY2008 (2008-12) $48.30B -0.3% N/A — 2008–09 Cycle Stress
FY2007 (2007-12) $48.42B — N/A — Standard

Year-by-Year Projections

EPS growth decays from initial rate to terminal rate over the projection period.

Year Growth Rate EPS Stock Price Present Value

Price Projection

Sensitivity Analysis

How intrinsic value changes with different growth and discount rate assumptions.

LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $28.86 · IV 25.6%

PFE Valuation Scenarios: Simulated 5-Day Put-Wall Income & Directional Payoffs

Compare $2,886 for 100 PFE shares against defined-margin put credit buffers and 5-day directional option spreads.

PUT-WALL MONTHLY INCOME Liq A

Jan 15 '27 $27 / $25 Bull Put Spread

Sell 2x $27P · Buy 2x $25P · 59d

Net Entry $58 Credit
Max Credit / Yield +$58 (+17.0% RoM)
Max Risk / Buffer -7.4% Cushion ($342 Mgn)
5d Edge & Liquidity 77% PoP · Liq A
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq A

Dec 18 $29 / $28 Bear Put Spread

Buy 2x $29P · Sell 2x $28P · 31d

Net Entry $76 Debit
T+5d @ -5% Drop +$54 (+71%)
Max Risk / Buffer $76 Capped
5d Edge & Liquidity 1.1x R:R · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 24 $27P / $29-$31C Seagull

Sell 1x $27P · Buy 1x $29/$31C · 37d

Net Entry $40 Debit
T+5d @ +5% Move +$66 (+14.3% RoM)
Max Risk / Buffer -6.4% Put Cushion ($459 Mgn)
5d Edge & Liquidity 0.7x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Model Inputs
Base EPS $2.95
Current Price $28.45
Historical PE 9.3x
Analyst Growth Est. -3.4%
How It Works

Growth Decay Model: We project EPS growth that gradually slows from the initial rate to a terminal rate (typically 3-4%, matching long-term GDP growth).

Terminal Value: At the end of the projection period, we apply an exit PE multiple to estimate the future stock price.

Discounting: Future values are discounted back to today using your required rate of return (discount rate).

Portfolios Holding PFE